This is a news story, published by Yahoo Finance, that relates primarily to Leqembi news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Leqembi sales. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest biosimilars business news, Leqembi news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
disease drug LeqembiReuters
•80% Informative
Biogen lifted its full-year earnings forecast as launch of new treatments and cost-cutting program are expected to make up for falling sales of its older multiple sclerosis medicines.
Drugmaker has cut jobs, bolstered its pipeline for rare disease medicines through takeover deals and unveiled new products, such as Alzheimer's disease drug Leqembi .
VR Score
92
Informative language
98
Neutral language
79
Article tone
formal
Language
English
Language complexity
45
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links